Program Information

A non-CME educational program sponsored by RMEI Medical Education, LLC, open to all ATS 2019 International Conference attendees.

Tuesday, May 21, 2019
6:30 PM – 8:30 PM

Hyatt Regency Dallas
Landmark Ballroom A
300 Reunion Boulevard
Dallas, TX 75207

Gain valuable insights on recognition and management of patients with alpha-1 antitrypsin deficiency (AATD) lung disease!

Hear from these clinical experts and a real patient living with AATD during this dynamic series of panel discussions. Each panel addresses a different challenging case of a patient with AATD – such as high-risk genotype and low FEV – as well as diagnostic considerations and therapeutic interventions, including augmentation therapy.

During registration, you are encouraged to SUBMIT your challenging AATD clinical cases for review and live discussion by the full faculty panel.


6:30 PM – 7:00 PM
Registration and Dinner
7:00 PM – 7:05 PM
Welcome and Introductions
Robert A. Sandhaus, MD, PhD, FCCP
7:05 PM – 7:20 PM
AATD Clinical Case 1
Delayed Diagnosis AND Panel Discussion
Robert A. Sandhaus, MD, PhD, FCCP and Panel including Live Patient
7:20 PM – 7:25 PM
Audience Q&A
7:25 PM – 7:40 PM
AATD Clinical Case 2
Interpreting Genetic Testing AND Panel Discussion
James M. Stocks, MD and Panel including Live Patient
7:40 PM – 7:45 PM
Audience Q&A
7:45 PM – 8:00 PM
AATD Clinical Case 3
Treatment Selection AND Panel Discussion
Michael Campos, MD and Panel including Live Patient
8:00 PM – 8:10 PM
Audience Q&A and Post-test
8:10 PM – 8:30 PM
Audience Submitted Cases, Panel Discussion, and Closing


Robert A. Sandhaus, MD, PhD, FCCP (Chair)
Professor, Medicine
Director, Alpha-1 Program
National Jewish Health
Denver, CO
James M. Stocks, MD
Professor, Medicine
Department of Medicine
University of Texas Health Science Center at Tyler
Tyler, TX
Michael Campos, MD
Associate Professor, Medicine
Division of Pulmonary, Allergy, Critical Care
University of Miami School of Medicine
Miami, FL

Upon completion of this educational activity, participants should be able to:

  • Demonstrate improved ability to identify AATD in their patients affected by chronic obstructive pulmonary disease (COPD)
  • Identify patients at risk for AATD and implement guideline-recommended testing
  • Discuss the efficacy data and guideline recommendations for augmentation therapy use to treat AATD
  • Develop individualized treatment plans for patients with AATD using all available clinical information about the patient, including information about physiological health status

This educational activity is designed for clinicians who can impact recognition and referral to specialists for alpha-1 antitrypsin deficiency (AATD) lung disease.

This educational activity was independently developed by RMEI Medical Education, LLC, in collaboration with the Postgraduate Institute for Medicine (PIM). All faculty and planner conflicts of interest were identified and resolved, and PIM has reviewed the content and determined it to be fair, balanced, and without commercial bias.

This activity is supported by independent educational grants from CSL Behring, Grifols, and Shire, now part of Takeda.

There is no fee for this educational activity.

Please contact Nicole Neely at

Facebook  Twitter

Additional educational activities offered by RMEI Medical Education, LLC can be found
at or by calling toll-free (866) 770-RMEI.